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Summary
Background Excimer laser coronary angioplasty is reported
to give excellent procedural results for treatment of
complex coronary lesions, but this method has not been
compared with balloon angioplasty in a randomised trial.
Methods Patients (n=308) with stable angina and coronary
lesions longer than 10 mm on visual assessment were
included. 151 patients (158 lesions) were assigned
randomly to laser angioplasty and 157 (167 lesions) to
balloon angioplasty. The primary clinical endpoints were
death, myocardial infarction, coronary bypass surgery, or
repeat coronary angioplasty of the randomised segment
during 6 months of follow-up. The primary angiographic
end-point was the minimal lumen diameter at follow-up in
relation to the baseline value (net gain), as determined by
quantitative coronary angiography.
Findings Laser angioplasty was followed by balloon
angioplasty in 98% of procedures. The angiographic
success rate was 80% in patients treated with laser
angioplasty compared with 79% in patients treated with
balloon angioplasty. There were no deaths. Myocardial
infarction, coronary bypass surgery, and repeat angioplasty
occurred in 4&middot;6%, 10&middot;6%, and 21&middot;2%, respectively, of the
patients in the laser angioplasty group compared with
5&middot;7%, 10&middot;8%, and 18&middot;5% of the balloon angioplasty group.
Net mean (SD) gain in minimal lumen diameter was 0&middot;40
(0&middot;69) mm in patients treated with laser angioplasty and
0&middot;48 (0&middot;66) mm in those treated with balloon angioplasty
(p=0&middot;34). The restenosis rate (>50% diameter stenosis)
was 51&middot;6% in the laser angioplasty group versus 41&middot;3% in
the balloon angioplasty group (p=0&middot;13).
Interpretation Excimer laser angioplasty followed by
balloon angioplasty provides no benefit additional to
balloon angioplasty alone with respect to the initial and
long-term clinical and angiographic outcome in the
treatment of obstructive coronary artery disease.
University of Amsterdam Department of Cardiology
(Y E A Appelman MD, J J Piek MD, G K David MD) and Department of
Clinical Epidemiology and Biostatistics (Prof J G P Tijssen PhD,
M J Koelemay MD) Academic Medical Centre, Meibergdreef 9,
1105 AZ Amsterdam, Netherlands; Thoraxcenter, Rotterdam,
Netherlands (S Strikwerda MD, P J de Feyter MD, P W Serruys MD,
E W J Montauban van Swijndregt); the Miami Heart Institute,
Miami, USA (J R Margolis MD); and Catharina Hospital, Eindhoven,
Netherlands (J J Koolen MD)
Correspondence to: Dr Jan J Piek
Lancet 1996; 347: 79-84
Introduction
Excimer laser coronary angioplasty (ELCA) is one
technique used for treatment of obstructive coronary
artery disease. The excimer laser system exhibits
favourable characteristics for ablation of atherosclerotic
tissue compared with other laser devices because of its
small penetration depth and the induction of limited
damage to the vascular wall.1-4 Compared with results
after balloon angioplasty,5 prospective non-randomised
studies of ELCA6-8 showed a substantial improvement in
primary success rate and procedural complications in
patients with complex coronary lesions. These promising
results warranted a randomised trial to establish the role
of laser angioplasty as an alternative approach in the
treatment of obstructive coronary artery disease. Most
patients considered suitable for coronary angioplasty have
long (>10 mm) coronary lesions. These considerations
led us to undertake a randomised trial to evaluate initial
and long-term clinical and angiographic outcome of




After completion of a pilot phase including 71 patients,9 the
multicentre Amsterdam-Rotterdam (AMRO) trial was started in
September, 1991, and completed in November, 1993. Based
upon the results of nonrandomised studies of ELCA, we
expected the primary procedural success rate after ELCA to be
greater than 85% and less than 70% after balloon angioplasty.
Thus, with an alpha-error of 0-05 and a beta error of 0-20, 120
patients with complete follow-up were required in each treatment
group. 300 patients were considered necessary for inclusion
taking into account that 20% of the patients were not eligible for
follow-up angiography. All patients (either with single or
multivessel disease) with stable angina pectoris, coronary lesions
longer than 10 mm on visual assessment, and total or functional
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occlusions (thrombolysis in myocardial infarction [TIMI] flow
grade 0 or 1)’" who were suitable for coronary angioplasty were
screened for inclusion in the trial. Clinical exclusion criteria
were: unstable angina, myocardial infarction within the previous
2 weeks, a life expectancy of less than 1 year, and factors that
made clinical or angiographic follow-up difficult. Angiographic
exclusion criteria were: intended angioplasty of a venous bypass
graft, unprotected left main disease, extreme tortuosity of the
vessel, highly eccentric lesions, vessels with ostial lesions,
angulated lesions of more than 45&deg;, bifurcation lesions, aorta-
ostial lesions, lesions with angiographic evidence of a thrombus
or dissection, and total occlusions with a low likelihood of
passage with a guide wire."The protocol was approved by the
institutional review boards of the participating centres.
Randomisation
Patients were assigned randomly by telephone from a central
office to laser angioplasty or balloon angioplasty after eligibility
had been established and written informed consent obtained.
Lesions suitable for balloon angioplasty only were indicated
before the randomisation in patients with multiple lesions. All
coronary lesions in a patient who fulfilled the selection criteria
were treated according to the same treatment allocation.
Laser angioplasty and balloon angioplasty
Patients’ anti-anginal medication was continued until the
procedure. A calcium antagonist (nifedipine 20 mg three times a
day) was added during in-hospital stay. Acetyl salicylic acid
(250-500 mg daily) was given a day before the procedure and
continued for 6 months afterwards. The excimer laser systems
(wavelength 308 nm) used were: the Dymer 200+ (Advanced
Interventional Systems Inc, Irvine, CA, USA), with a pulse
duration of 210 ns and a repetition rate of 20 Hz, delivered by
multifibre over wire laser catheters with a diameter of 1-3, 1-6, or
2-0 mm, at a fluence of 45-65 mJ/mm2; and the CVX-300 system
(Spectranetics, Colorado Springs, CO, USA), which emits a
pulse duration of 135 ns at a repetition rate of 25 Hz, delivered
by 1-4, 1-7 or 2-0 mm laser catheters, with a similar fluence. The
1-3z mm laser catheter was used after its introduction in 1992.
The 1-3/1-4 mm laser catheter was used for vessels with diameter
of 1-8-2-3 mm, 1-6/1-7 mm laser catheter for vessels with a
diameter of 2-3-3-0 mm, and 2-0 mm laser catheter for vessels
with a diameter of 3-0 mm or more.
Cardiac catheterisation in all patients was by the percutaneous
femoral approach. Heparin was administered intravenously to
maintain the activated clotting time at more than 400 s and was
continued for at least 12 h after the procedure. After crossing the
lesion with the guide wire, the laser catheter was advanced at a
speed of about 1 mm/s. A larger laser catheter was used if the
angiographic result was unsatisfactory after one passage of the
laser catheter. Additional balloon angioplasty was done to
optimise the angiographic result. Serum creatine kinase
myocardial band concentration was measured routinely within
12 h after the initial procedure.
Quantitative coronary angiography
Quantitative coronary angiography, before and after the
procedure and at 6 months’ follow-up, was done after
administration of 0-1-0-3 mg of nitroglycerin or 1-3 mg of
isosorbine dinitrate by the intracoronary route. The angiograms
were analysed, in a central laboratory with the computer-assisted
cardiovascular angiography analysis system (CAAS) for
determination of the interpolated reference diameter, the
minimal lumen diameter, and the percentage diameter stenosis.12
Lesion length was determined by the maximal lesion length
between the crossing point of the computerised contour
detection line and the interpolated reference diameter line. If a
revascularisation procedure involving the treated segment had
been done before the angiography at 6 months, the most recent
angiogram obtained before this intervention was used as the
follow-up angiogram regardless of the timing of the second
intervention. If the time from intervention to follow-up
*Accordmg to classification of Canadian Cardiovascular Society ;13 taccordmg to
modified American College of Cardiology/American Heart Association task force
criteria ;14 taccordmg to TlMI-study group.10
Table 1: Base-line clinical and angiographic characteristics of
308 patients included in the intention-to-treat analysis
angiography was less than 3 months and no second intervention
was performed, the patient was asked to undergo angiography
again after 6 months. In the absence of a second angiogram at 6
months, the angiogram obtained most recently within the
previous 3 months was used.
Clinical and angiographic follow-up
Patients were seen after 1 and 6 months for an interview, physical
examination, and electrocardiogram. Follow-up coronary
angiography was done after 6 months. Repeat intervention was
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performed based on recurrent symptoms of angina and/or
objective evidence of myocardial ischaemia and a diameter
stenosis of more than 50% on visual assessment.
End-points
Primary clinical end-points were the occurrence of any of the
following events during a 6 month (&plusmn;1 month) follow-up:
cardiac death, myocardial infarction (based on the presence of at
least two of the following: typical chest pain and/or a serum rise
of more than twice the normal upper limit of the creatine kinase
myocardial band level and/or new pathological Q-wave formation
on the electrocardiogram), coronary bypass surgery, or a second
angioplasty because of recurrent symptoms of angina and/or
objective evidence of myocardial ischaemia by positive exercise
testing related to the randomised segment. Coronary bypass
surgery was defined to include emergency (within 12 h after the
procedure) or elective bypass surgery. All the clinical events were
reviewed by the critical-event committee, which was unaware of
the treatment assignment.
Primary angiographic end-point was the minimal lumen
diameter at the treated coronary site at 6 months follow-up
relative to the baseline value before the procedure (net gain).
Secondary end-points were: (1) laser success defined as a more
than 20% reduction in diameter stenosis after laser angioplasty
only on visual assessment; (2) angiographic success defined as a
less than 50% residual stenosis at the end of the procedure on
visual assessment; (3) acute gain defined as the minimal lumen
diameter at the treated coronary site at the end of the procedure
relative to the baseline value; (4) functional class at 6 months
according to the classification of the Canadian Cardiovascular
Society;" (5) the percent diameter stenosis at the treated
coronary site at 6 months’ follow-up relative to the baseline value
(net gain in percentage diameter stenosis); (6) restenosis rate
defined as a more than 50% diameter stenosis at the treated
coronary site at 6 months’ follow-up angiography as determined
by automated contour detection analysis; and (7) late loss
defined as the minimal lumen diameter at the treated site at 6
months’ follow-up relative to the minimal lumen diameter after
the procedure.
Statistical analysis
Continuous variables (age, reference diameter, lesion length,
percentage diameter stenosis, and minimal lumen diameter) were
expressed as mean (SD) and were compared with the unpaired
t test. Chi-squared analysis and Fisher’s exact test for two by two
tables were used to compare dichotomous variables. Clinical
events and angiographic complications were compared by relative
risk (RR) and 95% confidence interval. A p value less than 0-05
was considered statistically significant.
Results
Patient characteristics and randomisation
313 consecutive patients (330 lesions) were randomly
assigned to ELCA (155 patients/162 lesions) or balloon
angioplasty (158 patients/168 lesions). In five patients
(four assigned to laser angioplasty, one to balloon
angioplasty) the randomised segment was not treated. Of
these five patients, one withdrew his informed consent
and received balloon angioplasty. Two patients received
no coronary intervention because the randomised
segment showed a non-significant stenosis on the pre-
procedural angiogram. One patient was randomised
twice. The randomised segment was not treated in one
patient due to emergency coronary bypass surgery after
treatment of a non-randomised segment. These five
patients were not included in the final analysis since there
was no intention for treatment according to
randomisation.
Clinical and angiographic baseline characteristics of the
remaining 308 patients were similar and are shown in
table 1. Approximately half of the patients had multivessel
disease and 50% had experienced a previous myocardial
infarction. One third of the randomised coronary
segments were total or functional coronary occlusions
(TIMI 0 or 1).
158 lesions (151 patients) were randomly assigned to
ELCA. ELCA could not be done during 25 procedures
(25 patients) because of inability to cross the coronary
lesion with any guide wire (16 lesions), or cross-over to
balloon angioplasty (in total nine lesions: five because of
inability to pass the guide wire, three due to technical
failure of the laser system, and one because of presumed
risk of perforation). Of the remaining 133 lesions, 130
were treated with additional balloon angioplasty to obtain
an optimal angiographic result. Standalone laser
angioplasty was done with three lesions (2%). In 89 of the
133 (67%) treated lesions, a laser catheter not larger than
1-3/1-4 mm was used. In 19 lesions more than one laser
catheter was used.
167 lesions (157 patients) were randomly assigned to
balloon angioplasty. Balloon angioplasty was not done
during 22 procedures because the lesion could not be
crossed with a guide wire. In two patients the lesion could
not be crossed with the balloon; one of these was
successfully treated with laser angioplasty only and one
with laser angioplasty followed by balloon angioplasty.
The remaining 143 lesions were treated with balloon
angioplasty only.
Procedural results
The intention-to-treat analysis yielded a laser success by
visual assessment in 68% (107 lesions) of the 158 lesions
randomly assigned to ELCA. The angiographic success
rate by visual assessment was 80% (126 lesions) in
patients treated with ELCA compared with 79% (132
lesions) in patients treated with balloon angioplasty. The
angiographic success rate by quantitative coronary
angiography yielded similar results (80% in patients
assigned to ELCA compared with 78% in patients
assigned to balloon angioplasty).
The per protocol analysis yielded a success rate of 81%
after ELCA, which increased to 91% after additional
balloon angioplasty in patients allocated to ELCA
compared with an angiographic success rate of 92% in
*Death, myocardial infarction, coronary artery bypass grafting, or repeat angioplasty.
Table 2: Number (%) clinical events during the procedure and 6
months’ follow-up
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Figures are mean (SD) unless indicated.
*Referance values are interpolated diameters of normal vessels; tmlnlmallumen
diameter (MLD) at follow-up minus MLD before initial procedure; *MLO after initial
procedure minus MLD before initial procedure; &sect;MLD after initial procedure minus
MLD at follow-up.
Table 3: Quantitative analysis
patients allocated to balloon angioplasty (RR 0-99, 95%
CI 0-92-1-06; p=0-69).
There were no deaths. The incidence of Q-wave and
non-Q-wave myocardial infarctions was similar in both
groups (table 2). Most non-Q-wave myocardial
infarctions were small in both groups (maximal creatine
kinase-myocardial band concentration <20 U/L).
Seven patients (4-5%) randomly assigned to ELCA
required emergency coronary bypass surgery for the
following reasons: severe dissection of the randomised
segment (four patients, two of whom were treated with
stenting as a bridge to coronary bypass surgery),
perforation of the randomised segment (one patient),
extravasation of contrast (one patient), and unstable
angina (one patient). Emergency coronary bypass surgery
was required in three patients (1-9%) randomly assigned
to balloon angioplasty due to the occurrence of a severe
dissection.
Intimal dissections after completion of the procedure
occurred in 74 lesions (46-8%) in the patients treated
with ELCA. Most of these dissections (91 %) were minor:
type A in 27 lesions, type B in 22 lesions, and type C in
18 lesions. 15 The dissection rate was similar in patients
treated with balloon angioplasty (54-5% [91 lesions] of
patients) with 90% of dissections being minor: type A in
33 lesions, type B in 37 lesions, and type C in 12 lesions.
The procedure was complicated by coronary spasm in
seven patients treated with ELCA and in two patients
treated with balloon angioplasty (RR 3-70, 95% CI
0-78-17-54; p=0-1). Coronary perforation resulting in
haemodynamic deterioration occurred in one patient in
the ELCA group. This complication did not occur in the
balloon angioplasty group. The incidence of transient
occlusions of the randomised segment was significantly
higher in patients allocated to ELCA (ten patients) than
in those allocated to balloon angioplasty (one patient)
(10-57, 1-37-81-62; p=0005).
Clinical and angiographic outcomes
Clinical follow-up was complete in 98% of patients. A
primary clinical end-point was reached in 50 patients
(33-1%) treated with ELCA versus 47 patients (29-9%)
Figure: Cumulative frequency distribution curves
Minimal luminal diameters are shown before the initial intervention
(Pre), after the initial intervention (Post), and at follow-up angiography
(FU) for 151 patients treated with ELCA followed by additional balloon
angioplasty (ELCA+BA) and 157 patients treated with balloon
angioplasty (BA).
treated with balloon angioplasty. The incidences of
myocardial infarction, coronary bypass surgery, and
repeat angioplasty were similar in both groups (table 2).
Of the 151 patients randomly assigned to ELCA, 91
patients had no angina, 17 patients were graded as
functional class I, 31 patients as class II, 11 patients as
class III, and one patient as class IV according to the
Canadian Cardiovascular Society classification criteria’3
after 6 months’ follow-up. Of the 157 patients randomly
assigned to balloon angioplasty, 94 patients had no
angina, 17 patients were graded as functional class I, 27
patients as class II, 17 patients as class III, and two
patients as class IV after 6 months’ follow-up.
Follow-up angiography was not requested in 22 of the
151 patients in the ELCA group due to failure of the
initial procedure or coronary bypass surgery. Repeat
angiography was performed in 120 of the remaining 129
patients (93%). Follow-up angiography in the balloon
angioplasty group was requested in 131 of the 157
patients. Repeat angiography was done in 123 of these
patients (91%).
The net gain in minimal lumen diameter was similar in
both groups (table 3). The net gain in the ELCA group
was the result of a small, but non-significant, increase in
the acute gain minus a significant greater late loss
compared with the balloon angioplasty group. The
cumulative distribution of the minimal lumen diameter is
shown in the figure. The net mean (SD) gain in diameter
stenosis was 12-4 (25-1)% in the ELCA group versus 16-2
(25-9)% in the balloon angioplasty group (difference
- 3-9%, 95% CI -10-2 to 25; p=0-2). The incidence of
restenosis was 51-6% in the ELCA group compared with
41-3% in the balloon angioplasty group (p=0’13).
Discussion
The purpose of this randomised study was to compare the
clinical and angiographic outcome of ELCA versus
balloon angioplasty in the treatment of longer (> 10 mm)
coronary lesions. The more recent data from ELCA
registries indicate an increased use of additional balloon
angioplasty, which is consistent with the results of our
study.16-18 ELCA was followed by balloon angioplasty in
98% of procedures and therefore this trial in fact
comprises a comparison between combined ELCA and
balloon angioplasty versus balloon angioplasty only.
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We have shown that ELCA and balloon angioplasty for
the treatment of obstructive coronary artery disease yield
similar initial and long-term clinical and angiographic
outcomes in a selected cohort of patients with stable
angina and coronary lesions longer than 10 mm.
Clinical outcome for primary clinical and angiographic
end-points were similar in both groups. With respect to
the differences observed, there was a significantly higher
rate of transient occlusions in the ELCA group compared
with the balloon angioplasty group (6’3% vs 06%). This
may be explained by a response of the vascular wall due to
the mechanical effects caused by a fast expanding and
imploding vapour bubbles generated during ELCA. 19,21) In
general, this complication can be dealt with by
administration of intracoronary nitroglycerin and
additional balloon angioplasty.
Furthermore, there was a significant greater late loss in
minimal lumen diameter in the ELCA group compared
with the balloon angioplasty group. This finding may be
related to an accelerated degree of neointimal response
due to the mechanical effects of rapid vapour bubble
formation during laser application or a negative influence
on the geometric remodelling process after intracoronary
interventions.21,22 The greater late loss in minimal lumen
diameter resulted in a higher restenosis rate after ELCA-
51-6% versus 41-3% in the balloon angioplasty group.
It is difficult to compare the results of the present study
with data from non-randomised ELCA registries.6-8,16-18
Most of these registries focus attention on the initial
results after laser angioplasty and have reported
completeness of angiographic follow-up in 73-88% of
patients after successful ELCA. In our trial, the clinical
follow-up was complete in 98% of patients in both
groups, and angiographic follow-up was complete in 93%
of patients in the ELCA group and 91 % of patients in the
balloon angioplasty group. Furthermore, patients
included in the registries had a variety of coronary lesions
and the reported procedural success rates relate to those
procedures in which the coronary lesion was successfully
crossed with the guide wire. This explains why success
rates in our study based on the intention-to-treat analysis
are lower than in the ELCA registries, whereas results of
the per protocol analysis are comparable to the registry
data. Moreover, quantitative coronary analysis was
performed by an independent core laboratory, whereas
most angiographic results in the registries were based on
visual assessment or semi-quantitative assessment.
Finally, our trial, unlike the ELCA registries, included a
routinely measured serum creatine kinase band level after
each procedure.
A comparison of our balloon angioplasty group with
randomised trials of balloon angioplasty shows similar
results with respect to the clinical event rate and
complication rate.23-26 However, there was a marked
difference in our study in the procedural dissection rate
observed in both treatment groups. The high incidence of
dissections in our study might be related to selection of
more complex coronary lesions compared with the other
studies.5 Although the incidence of dissections was high,
the majority of dissections were type A, B , or C, which
are benign.
&deg; 
The serum level of the creatine kinase myocardial band
was systematically assessed in our trial. In this respect, the
periprocedural myocardial infarction rate (3-2%),
including Q and non-Q-wave myocardial infarctions,
cannot be compared with randomised balloon angioplasty
studies. The incidence of myocardial infarctions is low
compared with other studies in which the serum creatine
kinase myocardial band level was evaluated after
intracoronary interventions. These studies reported
substantial increases in enzymes in 10-20% of procedures
after balloon angioplasty or after application of other new
devices such as directional atherectomy or coronary
stenting.27,28
This first randomised clinical trial of ELCA versus
balloon angioplasty in obstructive coronary artery disease
demonstrated no additional benefit of ELCA.
Consequently, is there a role for ELCA in the treatment
of coronary lesions? It is important to mention that the
additional cost of ELCA favours the use of other
treatments. Several modifications of the current laser
technique are under investigation to optimise the results
of intracoronary laser angioplasty. Adjustments in laser
techniques to reduce formation of fast expanding and
imploding vapour bubbles include a flushing protocol,29
application of sequential laser fibre activation,3&deg; use of
lower energy fluence 31 and use of a new laser catheter
design in which homogeneous light distribution is
provided.
The results of this trial demonstrate no additional
benefit of ELCA over balloon angioplasty with the current
laser technique.
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